Dermatology

Topical roflumilast 0.3% improved IGA, PASI, itch, and symptom scores in plaque psoriasis with a safety profile comparable to vehicle.

KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.

Psychiatric comorbidities affect 25% of AD patients. Here, a check list on when to screen, when to refer, and how to prevent accumulated psychological burden in primary care.

A regular focus on mental heatlh during follow-ups with patients who have atopic dermatitis can be integrated simply with a few thoughtful questions.

Primary care is the ideal setting for management of atopic dermatitis, but certain scenarios, both physical and psychological, call for expert referral.

Controlling atopic dermatitis signs and symptoms early can alter social, emotional, and functional outcomes, sometimes dramatically.

Emotional red flags in AD, eg, sleep loss, isolation, hopelessness, often go unseen. Quick screening questions can surface the real burden individuals carry.

Growing up with AD carries lifelong emotional consequences. Clinicians who recognize these developmental risks can better support patients at every stage.

Up to 1 in 4 patients with atopic dermatitis face anxiety or depression. Primary care clinicians are key to identifying risk and supporting mental well-being.

FDA reviews roflumilast cream for young children with plaque psoriasis, potentially offering a first-of-its-kind topical treatment option.

LEO Pharma reveals promising 32-week results for tralokinumab, showing significant benefits for adults with moderate-to-severe hand eczema.

ACAAI 2025. Phase 3 data show tapinarof cream provides early, sustained improvement and good tolerability in children aged ≥2 years with atopic dermatitis.

Phase 2b findings show rezpegaldesleukin reduced ACQ-5 scores and improved key AD endpoints in participants with comorbid asthma.

Your daily dose of the clinical news you may have missed.

Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.

Psoriasis, lichen planus, and pityriasis rosea share overlapping presentations and comorbidities, but distinct pathophysiologies require accurate diagnosis and tailored therapeutic approaches.

The approval of roflumilast 0.05% provides a steroid-free, once-daily treatment option for safe and effective long-term management of pediatric eczema.

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

Patient Care tapped the rich trove of research and expert perspectives from the Revolutionizing Atopic Dermatitis 2025 conference to create a snapshot of the AD care of the future.

The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.

EADV 2025: Guttman-Yassky has great confidence in the future of agents that block the OX40 pathway, suggesting that they have the potential for disease modification.

Incyte announced the agency's decision, which was based on findings of significant reduction in atopic dermatitis signs and symptoms during the TRuE-AD3 clinical trial.

EADV 2025: Guttman-Yassky presented data from the phase 3 ROCKET-IGNITE trial and highlights its importance in the context of the global ROCKET development program.

The novel IL-22 blocker was associated with improvements in EASI as early as week 1 for lower doses and week 2 for the highest dose, compared with placebo.

EADV 2025: New phase 3 data reveal delgocitinib cream's efficacy for chronic hand eczema in adolescents, confirming its safety profile in adults.

Sanofi's amlitelimab, dosed every 4 or 12 weeks, was superior to placebo in efficacy and skin clearance, with efficacy increasing throughout the treatment period.

MRGPRX2 antagonism is the only known mechanism of action designed to modulate mast cells and sensory neurons, both key drivers of lesions and itch in AD.

Discover the latest advancements in atopic dermatitis treatment, including new topical agents and biologics, enhancing care for patients with moderate to severe conditions.

Your daily dose of the clinical news you may have missed.